Tubridge, the first blood flow-oriented treatment device in China, was successfully applied in our hospital On December 19, the prospective, randomized controlled study of Tubridge revascularization device for the treatment of large intracranial aneurysms was officially launched in our center, and two patients with huge aneurysms were successfully treated free of charge. Li Tianxiao, Department of Interventional Medicine, Henan Provincial People’s Hospital Intracranial aneurysm is an abnormal bulge formed by the arterial vessels in the brain due to disease, injury or congenital factors that lead to localized weakness of the vessel wall and gradual expansion under the impact of long-term blood flow. Rupture of intracranial aneurysms often leads to subarachnoid hemorrhage, which has a high mortality and disability rate. 10-15% of patients die before they reach the hospital; the mortality rate is as high as 35% for a single hemorrhage and 60-80% for two hemorrhages, and the survivors are often disabled. Studies have shown that the 6-year risk of rupture is 13% for unruptured large aneurysms (13-24 mm) and 27% for giant aneurysms (>25 mm). The recurrence rate for large and giant aneurysms is 35-59%, and for every 1% increase in aneurysm size, the recurrence rate increases by 0.12%. It is due to the high morbidity and disability rate that the treatment of intracranial giant aneurysms has become a major challenge in clinical medicine today. Studies have proved that hemodynamics is the most important factor in the occurrence, growth, rupture, and even recurrence of aneurysms after interventional therapy. In recent years, the medical profession has put forward the treatment concept of blood flow steering device to address this problem, i.e., the application of dense mesh stents to remodel the local blood flow direction, directing the impacted blood flow in the aneurysm-carrying arteries to the distal normal blood vessels through the blood flow steering device to reduce the impact of local blood flow on the aneurysm, so as to reduce the blood flow in the aneurysm to the extent that intra-aneurysm thrombosis, mechanization, and occlusion can be significantly reduced. Secondly, stent implantation adds support to the implanted matrix, promotes the formation of endothelium, and has obvious repair and restoration effects on the neck of local aneurysm-carrying arteries, reducing the recurrence rate of aneurysms. Currently, there is no such product available in China, and the Tubridge revascularization device is the only epoch-making new product designed and developed on the basis of this theory for the treatment of giant aneurysms in China, and is currently undergoing a multi-center, randomized controlled clinical study. As a first-class cerebrovascular disease center in China, our department was invited to participate in this pilot study, becoming one of the five hospitals in China and the only unit in the province to use this device, and is currently recruiting subjects. Cerebrovascular Disease Ward, Henan Provincial People’s Hospital, Interventional Center, Henan Province, China Editor: He Yingkun